1 story in the last 7 days
The latest pfizer news, distilled by AI into sharp ~100-word summaries. ByteBrief tracks pfizer across dozens of tech sources and brings you only what matters, updated hourly. Tap any story for the full brief, or open the original source.
Pfizer's experimental weight-loss drug berobenatide requires only a monthly injection, unlike weekly shots from Novo Nordisk and Eli Lilly. Phase 2b trials showed comparable results. The market could reach $150 billion annually by 2035. Pfizer's drug offers convenience and scalability advantages.
Summaries by ByteBrief